Arginine deprivation therapy for malignant melanoma

Jung Ki Yoon, Arthur E. Frankel, Lynn G. Feun, Suhendan Ekmekcioglu, Kevin B. Kim

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Despite recent development of promising immunotherapeutic and targeted drugs, prognosis in patients with advanced melanoma remains poor, and a cure for this disease remains elusive in most patients. The success of melanoma therapy depends on a better understanding of the biology of melanoma and development of drugs that effectively target the relevant genes or proteins essential for tumor cell survival. Melanoma cells frequently lack argininosuccinate synthetase, an essential enzyme for arginine synthesis, and as a result they become dependent on the availability of exogenous arginine. Accordingly, a therapeutic approach involving depletion of available arginine has been shown to be effective in preclinical studies. Early clinical studies have demonstrated sufficient antitumor activity to give rise to cautious optimism. In this article, the rationale for arginine deprivation therapy is discussed. Additionally, various strategies for depleting arginine are discussed and the preclinical and clinical investigations of arginine deprivation therapy in melanoma are reviewed.

Original languageEnglish (US)
Pages (from-to)11-19
Number of pages9
JournalClinical Pharmacology: Advances and Applications
Volume5
Issue number1
DOIs
StatePublished - Dec 21 2012

Fingerprint

Arginine
Melanoma
Therapeutics
Argininosuccinate Synthase
Pharmaceutical Preparations
Cell Survival
Enzymes
Neoplasms
Proteins

Keywords

  • Arginine deprivation
  • Argininosuccinate synthetase
  • Melanoma

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Arginine deprivation therapy for malignant melanoma. / Yoon, Jung Ki; Frankel, Arthur E.; Feun, Lynn G.; Ekmekcioglu, Suhendan; Kim, Kevin B.

In: Clinical Pharmacology: Advances and Applications, Vol. 5, No. 1, 21.12.2012, p. 11-19.

Research output: Contribution to journalArticle

Yoon, Jung Ki ; Frankel, Arthur E. ; Feun, Lynn G. ; Ekmekcioglu, Suhendan ; Kim, Kevin B. / Arginine deprivation therapy for malignant melanoma. In: Clinical Pharmacology: Advances and Applications. 2012 ; Vol. 5, No. 1. pp. 11-19.
@article{9ff5f8152545404ebcef5c2c11f53d83,
title = "Arginine deprivation therapy for malignant melanoma",
abstract = "Despite recent development of promising immunotherapeutic and targeted drugs, prognosis in patients with advanced melanoma remains poor, and a cure for this disease remains elusive in most patients. The success of melanoma therapy depends on a better understanding of the biology of melanoma and development of drugs that effectively target the relevant genes or proteins essential for tumor cell survival. Melanoma cells frequently lack argininosuccinate synthetase, an essential enzyme for arginine synthesis, and as a result they become dependent on the availability of exogenous arginine. Accordingly, a therapeutic approach involving depletion of available arginine has been shown to be effective in preclinical studies. Early clinical studies have demonstrated sufficient antitumor activity to give rise to cautious optimism. In this article, the rationale for arginine deprivation therapy is discussed. Additionally, various strategies for depleting arginine are discussed and the preclinical and clinical investigations of arginine deprivation therapy in melanoma are reviewed.",
keywords = "Arginine deprivation, Argininosuccinate synthetase, Melanoma",
author = "Yoon, {Jung Ki} and Frankel, {Arthur E.} and Feun, {Lynn G.} and Suhendan Ekmekcioglu and Kim, {Kevin B.}",
year = "2012",
month = "12",
day = "21",
doi = "10.2147/CPAA.S37350",
language = "English (US)",
volume = "5",
pages = "11--19",
journal = "Clinical Pharmacology: Advances and Applications",
issn = "1179-1438",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Arginine deprivation therapy for malignant melanoma

AU - Yoon, Jung Ki

AU - Frankel, Arthur E.

AU - Feun, Lynn G.

AU - Ekmekcioglu, Suhendan

AU - Kim, Kevin B.

PY - 2012/12/21

Y1 - 2012/12/21

N2 - Despite recent development of promising immunotherapeutic and targeted drugs, prognosis in patients with advanced melanoma remains poor, and a cure for this disease remains elusive in most patients. The success of melanoma therapy depends on a better understanding of the biology of melanoma and development of drugs that effectively target the relevant genes or proteins essential for tumor cell survival. Melanoma cells frequently lack argininosuccinate synthetase, an essential enzyme for arginine synthesis, and as a result they become dependent on the availability of exogenous arginine. Accordingly, a therapeutic approach involving depletion of available arginine has been shown to be effective in preclinical studies. Early clinical studies have demonstrated sufficient antitumor activity to give rise to cautious optimism. In this article, the rationale for arginine deprivation therapy is discussed. Additionally, various strategies for depleting arginine are discussed and the preclinical and clinical investigations of arginine deprivation therapy in melanoma are reviewed.

AB - Despite recent development of promising immunotherapeutic and targeted drugs, prognosis in patients with advanced melanoma remains poor, and a cure for this disease remains elusive in most patients. The success of melanoma therapy depends on a better understanding of the biology of melanoma and development of drugs that effectively target the relevant genes or proteins essential for tumor cell survival. Melanoma cells frequently lack argininosuccinate synthetase, an essential enzyme for arginine synthesis, and as a result they become dependent on the availability of exogenous arginine. Accordingly, a therapeutic approach involving depletion of available arginine has been shown to be effective in preclinical studies. Early clinical studies have demonstrated sufficient antitumor activity to give rise to cautious optimism. In this article, the rationale for arginine deprivation therapy is discussed. Additionally, various strategies for depleting arginine are discussed and the preclinical and clinical investigations of arginine deprivation therapy in melanoma are reviewed.

KW - Arginine deprivation

KW - Argininosuccinate synthetase

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84871890551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871890551&partnerID=8YFLogxK

U2 - 10.2147/CPAA.S37350

DO - 10.2147/CPAA.S37350

M3 - Article

C2 - 23293541

AN - SCOPUS:84871890551

VL - 5

SP - 11

EP - 19

JO - Clinical Pharmacology: Advances and Applications

JF - Clinical Pharmacology: Advances and Applications

SN - 1179-1438

IS - 1

ER -